NASDAQ:PHIO Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis $3.98 +0.14 (+3.64%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.55▼$4.0750-Day Range$3.60▼$7.0652-Week Range$3.35▼$29.07Volume77,473 shsAverage Volume66,197 shsMarket Capitalization$2.03 millionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Phio Pharmaceuticals alerts: Email Address Phio Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside803.4% Upside$36.00 Price TargetShort InterestHealthy1.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.22Based on 2 Articles This WeekInsider TradingAcquiring Shares$749 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($16.38) to $34.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.86 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPhio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePhio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Phio Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.17% of the float of Phio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhio Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phio Pharmaceuticals has recently decreased by 62.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHIO. Previous Next 3.5 News and Social Media Coverage News SentimentPhio Pharmaceuticals has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Phio Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for PHIO on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $749.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.59% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by Institutions57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phio Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($16.38) to $34.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phio Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phio Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Phio Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About Phio Pharmaceuticals Stock (NASDAQ:PHIO)Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Read More PHIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHIO Stock News HeadlinesMay 19, 2024 | investing.comPhio Pharmaceuticals secures investment from TRITON FundsMay 17, 2024 | finanznachrichten.dePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures New InvestorJuly 27, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.May 17, 2024 | globenewswire.comPhio Pharmaceuticals Secures New InvestorMay 16, 2024 | finance.yahoo.comPhio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)May 15, 2024 | globenewswire.comPhio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation StudyMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phio Pharmaceuticals Amid Promising INTASYL Technology and PH-762 Clinical ProgressMay 10, 2024 | finanznachrichten.dePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business UpdateJuly 27, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.May 9, 2024 | globenewswire.comPhio Pharmaceuticals Reports Q1 2024 Results and Provides Business UpdateApril 30, 2024 | globenewswire.comPhio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)April 24, 2024 | investing.comPhio Pharmaceuticals reports progress on cancer therapy PH-762April 22, 2024 | benzinga.comWhy Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?April 22, 2024 | finance.yahoo.comIntratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsApril 22, 2024 | globenewswire.comIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsApril 16, 2024 | globenewswire.comPhio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)April 11, 2024 | globenewswire.comPhio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)April 3, 2024 | finance.yahoo.comNational Spotlight Features Phio’s Innovative RNAi Technology PlatformSee More Headlines Receive PHIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHIO CUSIPN/A CIK1533040 Webphiopharma.com Phone(508) 767-3861Fax508-767-3862Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$36.00 Low Stock Price Target$36.00 Potential Upside/Downside+803.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($29.2529) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-123.19% Return on Assets-98.58% Debt Debt-to-Equity RatioN/A Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$18.57 per share Price / Book0.21Miscellaneous Outstanding Shares510,000Free Float507,000Market Cap$2.03 million OptionableNot Optionable Beta1.45 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Robert J. Bitterman (Age 73)President, CEO & Chairman Comp: $380.25kMs. Caitlin Kontulis (Age 38)VP of Finance & Administration and Secretary Ms. Linda M. MahoneySenior Vice President of DevelopmentKey CompetitorsAlterity TherapeuticsNASDAQ:ATHEChromocell TherapeuticsNYSE:CHROShuttle PharmaceuticalsNASDAQ:SHPHANEW MedicalNASDAQ:WENATC BiopharmNASDAQ:TCBPView All CompetitorsInsidersRobert J BittermanBought 111 shares on 6/6/2024Total: $749.25 ($6.75/share)Robert J BittermanBought 277 shares on 2/26/2024Total: $2,268.63 ($8.19/share)View All Insider Transactions PHIO Stock Analysis - Frequently Asked Questions How have PHIO shares performed this year? Phio Pharmaceuticals' stock was trading at $6.84 on January 1st, 2024. Since then, PHIO stock has decreased by 41.7% and is now trading at $3.9850. View the best growth stocks for 2024 here. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp. (NASDAQ:PHIO) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($4.23) earnings per share for the quarter. When did Phio Pharmaceuticals' stock split? Phio Pharmaceuticals's stock reverse split on Friday, July 5th 2024. The 1-9 reverse split was announced on Friday, July 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. How do I buy shares of Phio Pharmaceuticals? Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Boxlight (BOXL) and Evofem Biosciences (EVFM). This page (NASDAQ:PHIO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
